Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study - PDF (Russian)

Copyright (c) 2022 Nesterova E.S., Saydullaeva A.F., Sherstnev D.G., Shelekhova T.V., Klitochenko T.Y., Khusainova G.N., Lysenko I.B., Lyalina I.S., Demchenkova M.V., Orlova S.A., Proydakov A.V., Betrozova M.V., Fadeeva N.V., Gofman A.A., Marchenko Y.M., Voloshin S.V., Pashneva E.A., Sarzhevskiy V.O., Ishchanov D.G., Poddubnaya I.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies